• Tamoxifen and Potent CYP2D6 Inhibitors: A Potentially Lethal Interaction

      Battley, JE; O’Connor, M; Barron, TI; O’Reilly, S (Irish Medical Journal, 2015-06)
      Tamoxifen has a well-established role in the management of oestrogen-receptor positive breast cancer halving the 5-year recurrence risk of early stage breast cancer, reducing mortality and controlling metastasis. It is an inactive pro-drug which is activated by the hepatic cytochrome P450 system.